Thrombosis Drugs Market To Surpass US$ 47,000 Mn by 2026, expanding at a CAGR of 9.5% from 2018 to 2030

Global Thrombosis Drugs Market – An Overview

Over the forecast period of 2018 to 2026, notable growth would be charted by global thrombosis drugs market, creating a string of advantageous opportunities and driving the market valuation to a higher worth. Multiple factors of growth are helping the global thrombosis drugs market stay on an upward and steep growth curve over the stated period. Some of these include poor lifestyle choices gaining foothold among consumers, increasing burden of cardiovascular diseases, and growing government efforts towards improvement in healthcare outcomes.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111997

A detailed overview of trends and drivers that are contributing significantly to growth in the global thrombosis drugs market can be found below:

Number of people in the geriatric age group is increasing and it is increasing at a rapid pace. As per research undertaken recently, there would be an increase from approximately 970million in 2017 to 2 billion in 2050 in the number of people aged 60 and above. This phenomenon is going to be quite pronounced in regions of Europe and North America where one in every four people will be aged 65 and above by this year. One in every six people will be the ratio of people in this age group across the world. This demographic is a major consumer of thrombosis drugs and is therefore set to propel notable growth in the market.

Research and development in the market is witnessing increase in activity and intensity – a result of growing number of cases of cardiovascular diseases. Poor diet and habits such as excessive drinking and smoking is leading to increase in incidence of these diseases across the globe. This is contributing massively to growth that is anticipated in the global thrombosis drugs market. Additionally, obesity or being over-weight is also increasing the risk of CVD, driving demand for thrombosis drugs by a notable factor over the forecast period,

Global Thrombosis Drugs Market – Snapshot

Thrombosis is the medical term for an abnormal blood clot in an artery or vein. Thrombosis drugs are used to prevent or treat the blood clot, which can cause different thrombotic events. Medication to treat is likely to include anticoagulants drugs and thrombin inhibitors drugs. In terms of revenue, the global thrombosis market was valued at approximately US$ 20,000 Mn in 2017 and is anticipated to surpass US$ 47,000 Mn by 2026, expanding at a CAGR of 9.5% from 2018 to 2026. Rise in the number of patients affected by thrombosis and availability of new drugs formulation products with improved features are likely to fuel the global thrombosis drugs market from 2018 to 2026.

Thrombosis drugs are generally blood thinners. These drugs decrease the clotting power of blood and consequently, the chances of thrombosis events, such as pulmonary embolism, decrease. These drugs are available in the form of injection, capsule, and tablet. Key players are focusing on the development of drugs with better efficacy. For instance, Grifols Therapeutics Inc., a U.S.-based biotechnology company is projected to launch AT- lll, a new type of human recombinant thrombosis drugs for the indication of cardiac surgery cardiopulmonary bypass. Such key developments are likely to fuel the global thrombosis drugs market in the near future. However, the high price of non-vitamin K oral anticoagulant drugs and the availability of generic drugs are likely to hamper the global thrombosis drugs market during the forecast period.

View full report@ https://qyresearchmedical.com/report/thrombosis-drugs-market-drug-class-factor-xa-inhibitor-low-molecular-weight-heparin-p2y12-platelet-inhibitor-indication-pulmonary-embolism-atrial-fibrillation-deep-vein-thrombosis-distribution-channel-h-018-2030/111997

Several unmet needs are anticipated to create significant opportunities for existing players and new entrants in the global thrombosis drugs market. Rapid technological advancements in treatment therapies create opportunities for players operating in the global thrombosis drugs market. Ongoing developments in thrombosis drugs, such as Revo Biologic’s ATryn with continuous infusion of drugs are likely drive the thrombosis drugs market during the forecast period.

The global thrombosis drugs market can be segmented based on drug class, indication, distribution channel, and geography. In terms of drug class, the factor Xa inhibitor segment dominated the market and is expected to continue this trend during the forecast period, followed by the P2Y12 platelet inhibitor segment. Increasing preference for the usage of oral anticoagulant drugs with predictable dose release response is likely to propel the segment during the forecast period. The low molecular weight heparin drug class segment, is likely to lose market share during the forecast period owing to patent expiry. Based on indication, the pulmonary embolism segment led the market, in terms of revenue, in 2017. The segment is projected to continue to dominate the market during the forecast period. In terms of distribution channel, the hospital pharmacies segment accounted for a large share of the market in 2017 and is likely to continue its dominance during the forecast period.

In terms of geography, North America held a major share of the global thrombosis drugs market in 2017. High utilization rate of new oral anticoagulant drugs is a key factor that propels the market in North America. Moreover, favorable reimbursement for the treatment of different thrombosis events under Medicare policy also boosts the market in this region. In terms of revenue, the market in Europe and Asia Pacific is projected to expand during the forecast period. Rising prevalence of deep vein thrombosis and increasing awareness about the treatment and usage of drugs to treat different thrombosis events in countries such as Brazil and South Africa are likely to boost the market in Latin America and Middle East & Africa.

Key companies operating in the global thrombosis drugs market, which are profiled in the report, include GlaxoSmithKline plc., Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Bayer AG, Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH, and Pfizer, Inc. These players are adopting organic and in-organic growth strategies to expand their product offerings, strengthen their geographical reach, increase customer base, and gain market share. For instance, in September 2014, Mylan Inc., acquired the U.S. commercialization, marketing, and intellectual property rights relating to Arixtra (fondaparinux sodium) injection and the authorized generic of Arixtra from Aspen Global Incorporated. This acquisition enhanced Mylan Inc’s expansion opportunities in the U.S. market.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111997/2900

The global thrombosis drugs market has been segmented as follows:

Drug Class

  • Factor Xa Inhibitor
  • Low Molecular Weight Heparin
  • P2Y12 Platelet Inhibitor
  • Others

Indication

  • Pulmonary Embolism
  • Atrial Fibrillation
  • Deep Vein Thrombosis
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Israel
  • Rest of Middle East & Africa

TABLE OF CONTENT

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary : Global Thrombosis Drugs Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Drug Class Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Pipeline Analysis – Thrombosis Drugs Market
4.4. Thrombosis Drugs Sales Analysis
4.5. Thrombosis Drugs Market Value Chain Analysis
4.6. Global Thrombosis Drugs Market Analysis and Forecasts, 2016–2026
4.6.1. Market Revenue Projection (US$ Mn)
4.6.2. Market Outlook
4.7. Key Trends

Chapter 5. Global Thrombosis Drugs Market Analysis and Forecasts, by Drug Class
5.1. Key Findings / Developments
5.2. Introduction & Definition
5.3. Market Value Forecast, by Drug Class, 2017–2026
5.3.1. Factor Xa Inhibitor
5.3.2. Low Molecular Weight Heparin
5.3.3. P2Y12 Platelet Inhibitor
5.3.4. Others
5.4. Market Attractiveness, by Drug Class

Chapter 6. Global Thrombosis Drugs Market Analysis and Forecasts, by Indication
6.1. Key Findings / Developments
6.2. Introduction & Definition
6.3. Market Value Forecast, by Indication, 2017–2026
6.3.1. Pulmonary Embolism
6.3.2. Atrial Fibrillation
6.3.3. Deep Vein Thrombosis
6.3.4. Others
6.4. Market Attractiveness, by Indication

Chapter 7. Global Thrombosis Drugs Market Analysis and Forecasts, by Distribution Channel
7.1. Key Findings / Developments
7.2. Introduction & Definition
7.3. Market Value Forecast, by Distribution Channel, 2017–2026
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Distribution Channel

Chapter 8. Global Thrombosis Drugs Market Analysis and Forecasts, by Geography/Region
8.1. Geographical Representation
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

Chapter 9. North America Thrombosis Drugs Analysis and Forecast
9.1. Market Value Forecast, by Country, 2017–2026
9.1.1. U.S.
9.1.2. Canada
9.2. Market Value Share Analysis, by Drug Class, 2017–2026
9.3. Market Value Forecast, by Drug Class, 2016–2026
9.3.1. Factor Xa Inhibitor
9.3.2. Low Molecular Weight Heparin
9.3.3. P2Y12 Platelet Inhibitor
9.3.4. Others
9.4. Market Value Share Analysis, by Indication, 2017–2026
9.5. Market Value Forecast, by Indication, 2016–2026
9.5.1. Pulmonary Embolism
9.5.2. Atrial Fibrillation
9.5.3. Deep Vein Thrombosis
9.5.4. Others
9.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
9.7. Market Value Forecast, by Distribution Channel, 2016–2026
9.7.1. Hospital Pharmacies
9.7.2. Retail Pharmacies
9.7.3. Online Pharmacies
9.8. Market Attractiveness Analysis
9.8.1. By Country
9.8.2. By Drug Class
9.8.3. By Indication
9.8.4. By Distribution Channel

Chapter 10. Europe Thrombosis Drugs Market Analysis and Forecast
10.1. Market Value Forecast, by Country , 2017–2025
10.1.1. Germany
10.1.2. France
10.1.3. U.K.
10.1.4. Spain
10.1.5. Italy
10.1.6. Rest of Europe
10.2. Market Value Share Analysis, by Drug Class, 2017–2026
10.3. Market Value and Volume Forecast, by Drug Class, 2016–2026
10.3.1. Factor Xa Inhibitor
10.3.2. Low Molecular Weight Heparin
10.3.3. P2Y12 Platelet Inhibitor
10.3.4. Others
10.4. Market Value Share Analysis, by Indication, 2017–2026
10.5. Market Value Forecast, by Indication, 2016–2026
10.5.1. Pulmonary Embolism
10.5.2. Atrial Fibrillation
10.5.3. Deep Vein Thrombosis
10.5.4. Others
10.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
10.7. Market Value Forecast, by Distribution Channel, 2016–2026
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. Online Pharmacies
10.8. Market Attractiveness Analysis
10.8.1. By Country
10.8.2. By Drug Class
10.8.3. By Indication
10.8.4. By Distribution Channel

Chapter 11. Asia Pacific Thrombosis Drugs Market Analysis and Forecast
11.1. Market Value Forecast, by Country , 2017–2025
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. Australia & New Zealand
11.1.5. Rest of APAC
11.2. Market Value Share Analysis, by Drug Class, 2017–2026
11.3. Market Value and Volume Forecast, by Drug Class, 2016–2026
11.3.1. Factor Xa Inhibitor
11.3.2. Low Molecular Weight Heparin
11.3.3. P2Y12 Platelet Inhibitor
11.3.4. Others
11.4. Market Value Share Analysis, by Indication, 2017–2026
11.5. Market Value Forecast, by Indication, 2016–2026
11.5.1. Pulmonary Embolism
11.5.2. Atrial Fibrillation
11.5.3. Deep Vein Thrombosis
11.5.4. Others
11.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
11.7. Market Value Forecast, by Distribution Channel, 2016–2026
11.7.1. Hospital Pharmacies
11.7.2. Retail Pharmacies
11.7.3. Online Pharmacies
11.8. Market Attractiveness Analysis
11.8.1. By Country
11.8.2. By Drug Class
11.8.3. By Indication
11.8.4. By Distribution Channel

Chapter 12. Latin America Thrombosis Drugs Market Analysis and Forecast
12.1. Market Value Forecast, by Country, 2017–2025
12.1.1. Brazil
12.1.2. Mexico
12.1.3. Rest of LATAM
12.2. Market Value Share Analysis, by Drug Class, 2017–2026
12.3. Market Value and Volume Forecast, by Drug Class, 2016–2026
12.3.1. Factor Xa Inhibitor
12.3.2. Low Molecular Weight Heparin
12.3.3. P2Y12 Platelet Inhibitor
12.3.4. Others
12.4. Market Value Share Analysis, by Indication, 2017–2026
12.5. Market Value Forecast, by Indication, 2016–2026
12.5.1. Pulmonary Embolism
12.5.2. Atrial Fibrillation
12.5.3. Deep Vein Thrombosis
12.5.4. Others
12.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
12.7. Market Value Forecast, by Distribution Channel, 2016–2026
12.7.1. Hospital Pharmacies
12.7.2. Retail Pharmacies
12.7.3. Online Pharmacies
12.8. Market Attractiveness Analysis
12.8.1. By Country
12.8.2. By Drug Class
12.8.3. By Indication
12.8.4. By Distribution Channel

Chapter 13. Middle East & Africa Thrombosis Drugs Market Analysis and Forecast
13.1. Market Value Forecast, by Country, 2017–2025
13.1.1. GCC Countries
13.1.2. South Africa
13.1.3. Israel
13.1.4. Rest of Middle East & Africa
13.2. Market Value Share Analysis, by Drug Class, 2017–2026
13.3. Market Value and Volume Forecast, by Drug Class, 2016–2026
13.3.1. Factor Xa Inhibitor
13.3.2. Low Molecular Weight Heparin
13.3.3. P2Y12 Platelet Inhibitor
13.3.4. Others
13.4. Market Value Share Analysis, by Indication, 2017–2026
13.5. Market Value Forecast, by Indication, 2016–2026
13.5.1. Pulmonary Embolism
13.5.2. Atrial Fibrillation
13.5.3. Deep Vein Thrombosis
13.5.4. Others
13.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
13.7. Market Value Forecast, by Distribution Channel, 2016–2026
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
13.8. Market Attractiveness Analysis
13.8.1. By Country
13.8.2. By Drug Class
13.8.3. By Indication
13.8.4. By Distribution Channel

Chapter 14. Competition Landscape
14.1. Competition Matrix
14.1.1. GlaxoSmithKline plc. F. Hoffmann-La Roche Ltd.
14.1.2. Baxter International, Inc.
14.2. Company Profiles
14.2.1. GlaxoSmithKline plc.
14.2.1.1. Company Details
14.2.1.2. Company Description
14.2.1.3. Business Overview
14.2.1.4. SWOT Analysis
14.2.1.5. Financial Analysis
14.2.1.6. Strategic Overview
14.2.2. Baxter International, Inc.
14.2.2.1. Company Details
14.2.2.2. Company Description
14.2.2.3. Business Overview
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Johnson & Johnson
14.2.3.1. Company Details
14.2.3.2. Company Description
14.2.3.3. Business Overview
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Bayer AG
14.2.4.1. Company Details
14.2.4.2. Company Description
14.2.4.3. Business Overview
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Sanofi
14.2.5.1. Company Details
14.2.5.2. Company Description
14.2.5.3. Business Overview
14.2.5.4. SWOT Analysis
14.2.5.5. Financial Analysis
14.2.5.6. Strategic Overview
14.2.6. Bristol-Myers Squibb Company
14.2.6.1. Company Details
14.2.6.2. Company Description
14.2.6.3. Business Overview
14.2.6.4. SWOT Analysis
14.2.6.5. Financial Analysis
14.2.6.6. Strategic Overview
14.2.7. AstraZeneca plc
14.2.7.1. Company Details
14.2.7.2. Company Description
14.2.7.3. Business Overview
14.2.7.4. SWOT Analysis
14.2.7.5. Financial Analysis
14.2.7.6. Strategic Overview
14.2.8. Pfizer, Inc.
14.2.8.1. Company Details
14.2.8.2. Company Description
14.2.8.3. Business Overview
14.2.8.4. SWOT Analysis
14.2.8.5. Financial Analysis
14.2.8.6. Strategic Overview
14.2.9. Boehringer Ingelheim GmbH
14.2.9.1. Company Details
14.2.9.2. Company Description
14.2.9.3. Business Overview
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
14.2.10. Aspen Pharmacare Holdings Limited
14.2.10.1. Company Details
14.2.10.2. Company Description
14.2.10.3. Business Overview
14.2.10.4. SWOT Analysis
14.2.10.5. Strategic Overview

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111997/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi